5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
    Journal Article

    Vuky, J.; Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Grivas, P.; Bellmunt, J.; Powles, T.; Bajorin, D.; Hahn, N. M.; Savage, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Antibody-drug conjugates in prostate cancer
    Miscellaneous

    Danila, D. C.
    Clinical Advances in Hematology & Oncology (2020)

    Fulltext@MSK | Save
  • Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer
    Journal Article

    Zhang, Z.; Karthaus, W. R.; Lee, Y. S.; Gao, V. R.; Wu, C.; Russo, J. W.; Liu, M.; Mota, J. M.; Abida, W.; Linton, E.; more...
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: A decision centered on empowering patients and their physicians
    Editorial

    Subbiah, V.; Solit, D. B.; Chan, T. A.; Kurzrock, R.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer
    Meeting Abstract

    Murciano-Goroff, Y. R.; Lebow, E. S.; Tu, H. Y.; Li, M.; Lim, L. P.; Arbour, K. C.; Travis, W.; Solit, D. B.; Ladanyi, M.; Jones, D. R.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • The accuracy and usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability rating
    Journal Article

    Mitchell, A. P.; Dey, P.; Ohn, J. A.; Tabatabai, S. M.; Curry, M. A.; Bach, P. B.
    PharmacoEconomics (2020)

    Fulltext@MSK | Save
  • Distinguishing metastatic triple-negative breast cancer from nonmetastatic breast cancer using second harmonic generation imaging and resonance Raman spectroscopy
    Journal Article

    Bendau, E.; Smith, J.; Zhang, L.; Ackerstaff, E.; Kruchevsky, N.; Wu, B.; Koutcher, J. A.; Alfano, R.; Shi, L.
    Journal of Biophotonics (2020)

    Fulltext@MSK | Save
  • A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D. J.; Chudow, J.; DeNunzio, M.; Slovin, S. F.; Danila, D. C.; Morris, M. J.; Scher, H. I.; Rathkopf, D. E.
    Clinical Genitourinary Cancer (2020)

    Fulltext@MSK | Save
  • Androgens and overall survival in patients with metastatic castration-resistant prostate cancer treated with docetaxel
    Journal Article

    Ryan, C. J.; Dutta, S.; Kelly, W. K.; Middleberg, R.; Russell, C.; Morris, M. J.; Taplin, M. E.; Halabi, S.; the Alliance for Clinical Trials in Oncology Genitourinary Committee
    Clinical Genitourinary Cancer (2020)

    Fulltext@MSK | Save
  • Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
    Journal Article

    Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; more...
    BJU International (2020)

    Fulltext@MSK | Save